Sanofi (SNY) Income from Non-Controlling Interests (2009 - 2026)
Sanofi's Income from Non-Controlling Interests came in at $39.52 million for the quarter ended Jun 30, 2026, up 772.8% from $4.53 million a year earlier and up 462.6% from the prior quarter.
Sanofi (SNY) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Sanofi reported Income from Non-Controlling Interests of $46.7 million, down 34.5% year-over-year; for the year ended Dec 31, 2025, it was $42.93 million, down 31.6% from the prior year.
- Income from Non-Controlling Interests carries a five-year compound annual growth rate of 0.9% (years ended Dec 2020 to Dec 2025).
- Going back by year, Income from Non-Controlling Interests was $62.78 million in the year ended Dec 31, 2024, -$60.58 million in the year ended Dec 31, 2023, $119.1 million in the year ended Dec 31, 2022 (+79.7%) and $66.27 million in the year ended Dec 31, 2021 (+61.2%).
- The figure for the quarter ended Jun 30, 2026 represents the highest quarterly Income from Non-Controlling Interests since the quarter ended Dec 31, 2022.
- Year-over-year, Income from Non-Controlling Interests increased in five of the last six quarters, with growth averaging 150.8%.
- The fastest year-over-year change in Income from Non-Controlling Interests over five years came in the quarter ended Jun 30, 2026 (growth of 772.8%), and the weakest in the quarter ended Sep 30, 2022 (a decline of 90.1%).
- Business Quant data shows SNY's Income from Non-Controlling Interests at $7.02 million (quarter ended Mar 31, 2026), -$36.09 million (quarter ended Dec 31, 2025) and $36.24 million (quarter ended Sep 30, 2025) in the three quarters before the quarter ended Jun 30, 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,199.50 Bn | 1,168.08 Bn | 19.71 Bn | - |
| 2 | Johnson & Johnson | 635.17 Bn | 555.03 Bn | 17.30 Bn | - |
| 3 | AbbVie | 504.69 Bn | 477.85 Bn | 12.70 Bn | 3.00 Mn |
| 4 | Merck | 358.43 Bn | 312.86 Bn | 12.21 Bn | -2.00 Mn |
| 5 | Novartis Ag | 288.36 Bn | 252.75 Bn | 11.24 Bn | -7.00 Mn |
| 6 | Astrazeneca | 265.78 Bn | 239.54 Bn | 12.86 Bn | 1.00 Mn |
| 7 | Amgen | 237.46 Bn | 192.86 Bn | 7.24 Bn | - |
| 8 | Gilead Sciences | 193.65 Bn | 167.76 Bn | 6.22 Bn | - |
| 9 | Pfizer | 171.05 Bn | 118.00 Bn | 10.94 Bn | 10.00 Mn |
| 10 | Sanofi | 50.73 Bn | 17.66 Bn | 10.79 Bn | 39.52 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 39.52 Mn |
| Mar 31, 2026 | 7.02 Mn |
| Dec 31, 2025 | -20.95 Mn |
| Sep 30, 2025 | 36.24 Mn |
| Jun 30, 2025 | 4.53 Mn |
| Mar 31, 2025 | 22.09 Mn |
| Dec 31, 2024 | 12.82 Mn |
| Sep 30, 2024 | 31.85 Mn |
| Jun 30, 2024 | 4.31 Mn |
| Mar 31, 2024 | 14.12 Mn |
| Dec 31, 2023 | -3.23 Mn |
| Sep 30, 2023 | 14.15 Mn |
| Jun 30, 2023 | 13.07 Mn |
| Mar 31, 2023 | 15.03 Mn |
| Dec 31, 2022 | 58.15 Mn |
| Sep 30, 2022 | 3.02 Mn |
| Jun 30, 2022 | 48.02 Mn |
| Mar 31, 2022 | 8.98 Mn |
| Dec 31, 2021 | 11.44 Mn |
| Sep 30, 2021 | 30.66 Mn |
Sanofi Income from Non-Controlling Interests API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=SNY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-non-controlling-interests", "ticker": "SNY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=SNY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();